![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background
Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1.
Methods
The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported.
Results
In Kaplan–Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0.18) for PlGF and for sFlt-1 a HR = 1.0 (p = 0.8).
Conclusion
Our results point out that these biomarkers reflecting angiogenesis might not be suited to establish prognosis in CAD.
Financial & competing interests disclosure
The AtheroGene study is supported by a grant of the ‘Stiftung Rheinland-Pfalz für Innovation’, Ministry of Science and Education (AZ 15202–386261/545), Mainz, by the MAIFOR grant 2001 of the Johannes Gutenberg-University Mainz, Germany, and by grants from the Fondation de France (no. 2002004994), the French Ministry of Research (ACI IMPBIO 032619) and the Institut National de la Santé et de la Recherche Médicale (Programme National de Recherches sur les Maladies Cardiovasculaires A04052DS). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.